Chaudhuri KR - Search Results

1

Why do 'OFF' periods still occur during continuous drug delivery in Parkinson's disease?

Rota S, Urso D, van Wamelen DJ, Leta V, Boura I, Odin P, Espay AJ, Jenner P, Chaudhuri KR. Rota S, et al. Among authors: chaudhuri kr. Transl Neurodegener. 2022 Oct 13;11(1):43. doi: 10.1186/s40035-022-00317-x. Transl Neurodegener. 2022. PMID: 36229860 Free PMC article. Review.

2

Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared.

Chaudhuri KR, Dhawan V, Basu S, Jackson G, Odin P. Chaudhuri KR, et al. Mov Disord. 2004 Dec;19(12):1522-3. doi: 10.1002/mds.20330. Mov Disord. 2004. PMID: 15515009 No abstract available.

3

Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson's disease patients treated with cabergoline.

Dhawan V, Medcalf P, Stegie F, Jackson G, Basu S, Luce P, Odin P, Chaudhuri KR. Dhawan V, et al. Among authors: chaudhuri kr. J Neural Transm (Vienna). 2005 May;112(5):661-8. doi: 10.1007/s00702-005-0289-1. Epub 2005 Mar 23. J Neural Transm (Vienna). 2005. PMID: 15785862

4

International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study.

Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, Brown RG, Koller W, Barone P, MacPhee G, Kelly L, Rabey M, MacMahon D, Thomas S, Ondo W, Rye D, Forbes A, Tluk S, Dhawan V, Bowron A, Williams AJ, Olanow CW. Chaudhuri KR, et al. Mov Disord. 2006 Jul;21(7):916-23. doi: 10.1002/mds.20844. Mov Disord. 2006. PMID: 16547944

5

Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease.

Naidu Y, Chaudhuri KR. Naidu Y, et al. Among authors: chaudhuri kr. Expert Opin Drug Deliv. 2007 Mar;4(2):111-8. doi: 10.1517/17425247.4.2.111. Expert Opin Drug Deliv. 2007. PMID: 17335409 Review.

6

The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study.

Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, Ondo W, Abe K, Macphee G, Macmahon D, Barone P, Rabey M, Forbes A, Breen K, Tluk S, Naidu Y, Olanow W, Williams AJ, Thomas S, Rye D, Tsuboi Y, Hand A, Schapira AH. Chaudhuri KR, et al. Mov Disord. 2007 Oct 15;22(13):1901-11. doi: 10.1002/mds.21596. Mov Disord. 2007. PMID: 17674410

7

Clinical risk-benefit assessment of dopamine agonists.

Möller JC, Eggert KM, Unger M, Odin P, Chaudhuri KR, Oertel WH. Möller JC, et al. Among authors: chaudhuri kr. Eur J Neurol. 2008 Sep;15 Suppl 2:15-23. doi: 10.1111/j.1468-1331.2008.02214.x. Eur J Neurol. 2008. PMID: 18702738 Review.

8

Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment.

Chaudhuri KR, Schapira AH. Chaudhuri KR, et al. Lancet Neurol. 2009 May;8(5):464-74. doi: 10.1016/S1474-4422(09)70068-7. Lancet Neurol. 2009. PMID: 19375664 Review.

9

Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.

Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, Fox K, Mancini F, Canesi M, Odin P, Chaudhuri KR. Honig H, et al. Among authors: chaudhuri kr. Mov Disord. 2009 Jul 30;24(10):1468-74. doi: 10.1002/mds.22596. Mov Disord. 2009. PMID: 19425079 Clinical Trial.

10

Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease.

Antonini A, Chaudhuri KR, Martinez-Martin P, Odin P. Antonini A, et al. Among authors: chaudhuri kr. CNS Drugs. 2010 Feb;24(2):119-29. doi: 10.2165/11310940-000000000-00000. CNS Drugs. 2010. PMID: 20088619 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

463 results

Search Page